Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.16177. G protein-coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.
Stephen P H Alexander;Arthur Christopoulos;Anthony P Davenport;Eamonn Kelly;Alistair A Mathie;John A Peters;Emma L Veale;Jane F Armstrong;Elena Faccenda;Simon D Harding;Jamie A Davies;Maria Pia Abbracchio;George Abraham;Alexander Agoulnik;Wayne Alexander;Khaled Al-Hosaini;Magnus Bäck;Jillian G Baker;Nicholas M Barnes;Ross Bathgate;Jean-Martin Beaulieu;Annette G Beck-Sickinger;Maik Behrens;Kenneth E Bernstein;Bernhard Bettler;Nigel J M Birdsall;Victoria Blaho;Francois Boulay;Corinne Bousquet;Hans Bräuner-Osborne;Geoffrey Burnstock;Girolamo Caló;Justo P Castaño;Kevin J Catt;Stefania Ceruti;Paul Chazot;Nan Chiang;Bice Chini;Jerold Chun;Antonia Cianciulli;Olivier Civelli;Lucie H Clapp;Réjean Couture;Helen M Cox;Zsolt Csaba;Claes Dahlgren;Gordon Dent;Steven D Douglas;Pascal Dournaud;Satoru Eguchi;Emanuel Escher;Edward J Filardo;Tung Fong;Marta Fumagalli;Raul R Gainetdinov;Michael L Garelja;Marc de Gasparo;Craig Gerard;Marvin Gershengorn;Fernand Gobeil;Theodore L Goodfriend;Cyril Goudet;Lukas Grätz;Karen J Gregory;Andrew L Gundlach;Jörg Hamann;Julien Hanson;Richard L Hauger;Debbie L Hay;Akos Heinemann;Deron Herr;Morley D Hollenberg;Nicholas D Holliday;Mastgugu Horiuchi;Daniel Hoyer;László Hunyady;Ahsan Husain;Adriaan P IJzerman;Tadashi Inagami;Kenneth A Jacobson;Robert T Jensen;Ralf Jockers;Deepa Jonnalagadda;Sadashiva Karnik;Klemens Kaupmann;Jacqueline Kemp;Charles Kennedy;Yasuyuki Kihara;Takio Kitazawa;Pawel Kozielewicz;Hans-Jürgen Kreienkamp;Jyrki P Kukkonen;Tobias Langenhan;Dan Larhammar;Katie Leach;Davide Lecca;John D Lee;Susan E Leeman;Jérôme Leprince;Xaria X Li;Stephen J Lolait;Amelie Lupp;Robyn Macrae;Janet Maguire;Davide Malfacini;Jean Mazella;Craig A McArdle;Shlomo Melmed;Martin C Michel;Laurence J Miller;Vincenzo Mitolo;Bernard Mouillac;Christa E Müller;Philip M Murphy;Jean-Louis Nahon;Tony Ngo;Xavier Norel;Duuamene Nyimanu;Anne-Marie O'Carroll;Stefan Offermanns;Maria Antonietta Panaro;Marc Parmentier;Roger G Pertwee;Jean-Philippe Pin;Eric R Prossnitz;Mark Quinn;Rithwik Ramachandran;Manisha Ray;Rainer K Reinscheid;Philippe Rondard;G Enrico Rovati;Chiara Ruzza;Gareth J Sanger;Torsten Schöneberg;Gunnar Schulte;Stefan Schulz;Deborah L Segaloff;Charles N Serhan;Khuraijam Dhanachandra Singh;Craig M Smith;Leigh A Stoddart;Yukihiko Sugimoto;Roger Summers;Valerie P Tan;David Thal;Walter Wally Thomas;Pieter B M W M Timmermans;Kalyan Tirupula;Lawrence Toll;Giovanni Tulipano;Hamiyet Unal;Thomas Unger;Celine Valant;Patrick Vanderheyden;David Vaudry;Hubert Vaudry;Jean-Pierre Vilardaga;Christopher S Walker;Ji Ming Wang;Donald T Ward;Hans-Jürgen Wester;Gary B Willars;Tom Lloyd Williams;Trent M Woodruff;Chengcan Yao;Richard D Ye
2023-01-01
Abstract
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.16177. G protein-coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/465352
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Citazioni
16
131
114
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.